Stockscreener 앱 받기
6.95
9.28%
0.59
시간 외 거래:
7.10
0.15
+2.16%
전일 마감가:
$6.36
열려 있는:
$6.42
하루 거래량:
544.44K
Relative Volume:
0.96
시가총액:
$300.56M
수익:
-
순이익/손실:
$-110.66M
주가수익비율:
-2.2446
EPS:
-3.0963
순현금흐름:
$-97.76M
1주 성능:
-3.07%
1개월 성능:
+25.91%
6개월 성능:
+226.29%
1년 성능:
+36.54%
1일 변동 폭
$6.36
$7.04
1주일 범위
$6.30
$7.68
52주 변동 폭
$1.78
$8.4471
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
명칭
Kyverna Therapeutics Inc
전화
(510) 626-8331
주소
5980 HORTON STREET, EMERYVILLE
KYTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
6.95 | 275.04M | 0 | -110.66M | -97.76M | -3.0963 |
|
VRTX
Vertex Pharmaceuticals Inc
|
417.00 | 107.10B | 11.70B | 3.68B | 3.50B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
644.19 | 66.00B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.56 | 55.95B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
832.35 | 51.19B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.88 | 38.98B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-20 | 개시 | William Blair | Outperform |
| 2025-05-27 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-10-10 | 개시 | UBS | Buy |
| 2024-10-09 | 개시 | Rodman & Renshaw | Buy |
| 2024-07-03 | 개시 | H.C. Wainwright | Neutral |
| 2024-03-04 | 개시 | JP Morgan | Overweight |
| 2024-03-04 | 개시 | Leerink Partners | Outperform |
| 2024-03-04 | 개시 | Morgan Stanley | Overweight |
| 2024-03-04 | 개시 | Wells Fargo | Overweight |
모두보기
Kyverna Therapeutics Inc 주식(KYTX)의 최신 뉴스
How sentiment analysis helps forecast Kyverna Therapeutics Inc.2025 Key Lessons & Safe Entry Trade Signal Reports - newser.com
Why Kyverna Therapeutics Inc. stock remains undervaluedJuly 2025 Selloffs & Breakout Confirmation Trade Signals - newser.com
Will Kyverna Therapeutics Inc. stock keep outperforming rivalsJuly 2025 Rallies & Risk Controlled Swing Alerts - fcp.pa.gov.br
How Kyverna Therapeutics Inc. stock reacts to bond yieldsEarnings Overview Summary & Pattern Based Trade Signal System - fcp.pa.gov.br
Is Kyverna Therapeutics Inc. stock a buy before product launchesShare Buyback & Free Verified High Yield Trade Plans - newser.com
What the charts say about Kyverna Therapeutics Inc. todayPortfolio Update Summary & Reliable Intraday Trade Plans - newser.com
Pattern recognition hints at Kyverna Therapeutics Inc. upsideWeekly Market Report & Fast Moving Stock Watchlists - newser.com
Using economic indicators to assess Kyverna Therapeutics Inc. potentialJuly 2025 Rallies & Free Safe Entry Trade Signal Reports - newser.com
Can machine learning forecast Kyverna Therapeutics Inc. recoveryQuarterly Portfolio Report & Consistent Profit Trading Strategies - newser.com
Kyverna secures $150 million loan facility to advance autoimmune therapies By Investing.com - Investing.com Australia
Is Kyverna Therapeutics Inc. stock attractive for passive investorsEarnings Trend Report & Daily Growth Stock Tips - newser.com
Is Kyverna Therapeutics Inc. stock vulnerable to regulatory risks2025 Growth vs Value & Real-Time Volume Triggers - newser.com
Kyverna secures $150 million loan facility to advance autoimmune therapies - Investing.com
Kyverna Therapeutics Secures $150 Million Loan Facility - TipRanks
Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance - The Manila Times
[8-K] Kyverna Therapeutics, Inc. Reports Material Event | KYTX SEC FilingForm 8-K - Stock Titan
Kyverna (Nasdaq: KYTX) secures up to $150M non-dilutive financing maturing 2030 - Stock Titan
Kyverna Therapeutics Reports Positive Phase 2 Trial Results - MSN
Will Kyverna Therapeutics Inc. stock deliver long term returnsMarket Growth Review & Weekly Market Pulse Alerts - newser.com
Combining price and volume data for Kyverna Therapeutics Inc.Weekly Trade Summary & Safe Entry Momentum Tips - newser.com
Analysts Conflicted on These Healthcare Names: Kyverna Therapeutics, Inc. (KYTX), Disc Medicine (IRON) and Baxter International (BAX) - The Globe and Mail
Kyverna Therapeutics (KYTX) Price Target Increased by 16.46% to 23.46 - MSN
Kyverna Therapeutics, Inc. (KYTX) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Promising Phase 2 Data and Favorable Safety Profile Drive Buy Rating for Kyverna Therapeutics’ KYV-101 - TipRanks
What is HC Wainwright's Estimate for KYTX Q3 Earnings? - MarketBeat
Kyverna Therapeutics Advances in Lupus Nephritis Treatment with KYV-101 CAR T-Cell Therapy - MSN
Kyverna’s CAR T Therapy Sets 'New Efficacy Standard' in Myasthenia Gravis, De-Risking Phase III Trials - BioSpace
Amen at AANEM: Kyverna makes good on MG phase II promise - BioWorld MedTech
Kyverna Therapeutics Inc (KYTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
6.82%
1.34%
자본화:
|
볼륨(24시간):